MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.parkreldis.2025.108111

Медицинская библиотека · Parkinsonism & related disorders · 2025

Impact of dipeptidyl peptidase 4 inhibitor use on mortality in diabetic Parkinson's disease patients: A nationwide cohort study.

Park Mincheol, Lee Ho Kyung, Jin Yeonju, Yoo Sanghee, Kim Sung-Woo, Park Sojeong, Hong Jiwon, Hong Jin Yong, Hong Ickpyo, Baek Min Seok

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used oral hypoglycemic agents that enhance the bioavailability of active glucagon-like peptide-1 by inhibiting its degradation. Recent studies suggest possible neuroprotective effects of DPP4i in Parkinson's disease (PD); however, their association with mortality in PD is unclear.

METHODS

This retrospective cohort study analyzed the Korean National Health Insurance Service database. The cohort included 1093 adults diagnosed with both PD and type 2 diabetes (DM) between 2009 and 2019. We divided the participants into two groups: those not receiving DPP4i (PD-DPP4i+, n = 557) and those treated with DPP4i (PD-DPP4i-, n = 536). We used Kaplan-Meier survival analyses and Cox proportional hazard models to evaluate survival rates. Cox regression models included age, sex, number of comorbidities, and end-organ complication of DM including diabetic neuropathy and retinopathy as covariates.

RESULTS

The average age of the study participants was 73.40 (±7.67) years, and the majority were female (n = 674, 61.67 %). Kaplan-Meier analysis revealed the lower risk of mortality in the PD-DPP4i+ group (p < 0.0001). The Cox proportional hazards regression model indicated that PD-DPP4i+ group had a lower risk of death compared to PD-DPP4i- group (hazard ratio, 0.762; 95 % confidence interval, 0.611-0.949; p = 0.0153). Factors including male sex, older age at PD diagnosis, and the presence of more than two comorbidities were associated with an increased risk of death.

CONCLUSIONS

These findings suggest that the use of DPP4i in PD patients with co-existing DM is associated with lower risk of mortality.

Для цитирования: Park Mincheol, Lee Ho Kyung, Jin Yeonju, Yoo Sanghee, Kim Sung-Woo, Park Sojeong, Hong Jiwon, Hong Jin Yong, Hong Ickpyo, Baek Min Seok. Impact of dipeptidyl peptidase 4 inhibitor use on mortality in diabetic Parkinson's disease patients: A nationwide cohort study.. Parkinsonism & related disorders. 2025. DOI: 10.1016/j.parkreldis.2025.108111.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.